Wolverine Trading’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $4.6M | Buy |
40,825
+32,409
| +385% | +$3.68M | ﹤0.01% | 1456 |
|
|
2025
Q2 | $931K | Sell |
8,416
-31,289
| -79% | -$3.33M | ﹤0.01% | 2376 |
|
|
2025
Q1 | $4.44M | Buy |
39,705
+18,590
| +88% | +$1.92M | 0.01% | 1055 |
|
|
2024
Q4 | $1.94M | Buy |
21,115
+4,593
| +28% | +$414K | ﹤0.01% | 1985 |
|
|
2024
Q3 | $1.38M | Sell |
16,522
-34,036
| -67% | -$2.6M | ﹤0.01% | 2042 |
|
|
2024
Q2 | $3.47M | Buy |
50,558
+22,795
| +82% | +$1.52M | ﹤0.01% | 1204 |
|
|
2024
Q1 | $2.03M | Buy |
27,763
+2,877
| +12% | +$221K | ﹤0.01% | 1605 |
|
|
2023
Q4 | $2.02M | Buy |
24,886
+17,497
| +237% | +$1.36M | ﹤0.01% | 1721 |
|
|
2023
Q3 | $554K | Sell |
7,389
-5,808
| -44% | -$447K | ﹤0.01% | 2675 |
|
|
2023
Q2 | $1M | Buy |
13,197
+5,849
| +80% | +$466K | ﹤0.01% | 2007 |
|
|
2023
Q1 | $598K | Buy |
+7,348
| New | +$609K | ﹤0.01% | 2336 |
|
|
2022
Q4 | – | Sell |
-21,378
| Closed | -$1.69M | – | 4355 |
|
|
2022
Q3 | $1.35M | Sell |
21,378
-12,790
| -37% | -$807K | ﹤0.01% | 1715 |
|
|
2022
Q2 | $2.13M | Buy |
34,168
+2,409
| +8% | +$149K | ﹤0.01% | 1332 |
|
|
2022
Q1 | $1.9M | Sell |
31,759
-1,937
| -6% | -$124K | ﹤0.01% | 1817 |
|
|
2021
Q4 | $2.47M | Sell |
33,696
-66,074
| -66% | -$4.55M | ﹤0.01% | 1692 |
|
|
2021
Q3 | $7.08M | Sell |
99,770
-5,956
| -6% | -$418K | 0.01% | 1043 |
|
|
2021
Q2 | $7.18M | Buy |
105,726
+31,676
| +43% | +$2.12M | 0.01% | 872 |
|
|
2021
Q1 | $4.85M | Sell |
74,050
-86,937
| -54% | -$5.61M | 0.01% | 1137 |
|
|
2020
Q4 | $9.12M | Buy |
160,987
+72,637
| +82% | +$4.38M | 0.01% | 732 |
|
|
2020
Q3 | $5.49M | Buy |
88,350
+35,220
| +66% | +$2.44M | 0.01% | 808 |
|
|
2020
Q2 | $3.96M | Buy |
53,130
+2,459
| +5% | +$188K | 0.01% | 937 |
|
|
2020
Q1 | $3.85M | Sell |
50,671
-128,007
| -72% | -$8.85M | 0.01% | 916 |
|
|
2019
Q4 | $11.6M | Buy |
178,678
+47,108
| +36% | +$3.07M | 0.03% | 611 |
|
|
2019
Q3 | $8.28M | Buy |
131,570
+35,989
| +38% | +$2.35M | 0.02% | 619 |
|
|
2019
Q2 | $6.46M | Sell |
95,581
-35,282
| -27% | -$2.32M | 0.02% | 747 |
|
|
2019
Q1 | $8.51M | Buy |
130,863
+69,383
| +113% | +$4.61M | 0.02% | 569 |
|
|
2018
Q4 | $3.8M | Buy |
61,480
+54,471
| +777% | +$3.81M | 0.01% | 977 |
|
|
2018
Q3 | $541K | Sell |
7,009
-20,392
| -74% | -$1.54M | ﹤0.01% | 3029 |
|
|
2018
Q2 | $2.07M | Hold |
27,401
| – | – | ﹤0.01% | 1562 |
|
|
2018
Q1 | $2.07M | Sell |
27,401
-245,829
| -90% | -$19.5M | ﹤0.01% | 1562 |
|
|
2017
Q4 | $19.6M | Buy |
273,230
+259,106
| +1,835% | +$19.7M | 0.07% | 235 |
|
|
2017
Q3 | $1.14M | Sell |
14,124
-107,821
| -88% | -$8.24M | ﹤0.01% | 1785 |
|
|
2017
Q2 | $8.64M | Sell |
121,945
-76,788
| -39% | -$5.11M | 0.04% | 427 |
|
|
2017
Q1 | $13.4M | Buy |
198,733
+35,718
| +22% | +$2.51M | 0.07% | 278 |
|
|
2016
Q4 | $11.7M | Sell |
163,015
-44,690
| -22% | -$3.32M | 0.06% | 343 |
|
|
2016
Q3 | $16.2M | Buy |
207,705
+33,228
| +19% | +$2.7M | 0.08% | 288 |
|
|
2016
Q2 | $14.4M | Buy |
+174,477
| New | +$15.5M | 0.08% | 238 |
|
Other funds holding GILD
Wolverine Trading's GILD Position: Q3 2025 in Review
Wolverine Trading increased its Gilead Sciences (GILD) stake by 385% in Q3 2025, buying an estimated $3.68M and bringing the position to 40,825 shares worth $4.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1456.
Wolverine Trading first reported a position in GILD in Q2 2016 and has held it in 37 quarters since. The position peaked at $19.6M in Q4 2017. 2,026 funds tracked by Wall St. Rank hold GILD as of Q3 2025.
- Wolverine Trading held 40,825 shares of Gilead Sciences worth $4.6M as of Q3 2025.
- Wolverine Trading bought 32,409 Gilead Sciences shares in Q3 2025, an estimated $3.68M.
- Gilead Sciences made up ﹤0.01% of Wolverine Trading's portfolio in Q3 2025, its #1456 holding.
- Wolverine Trading first reported a position in Gilead Sciences in Q2 2016 and has held it in 37 quarters since.
- Wolverine Trading's Gilead Sciences position peaked at $19.6M in Q4 2017.
- 2,026 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.